Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 10Triple Negative Breast Neoplasms 2Stomach Neoplasms 2Pathologic Complete Response 1Neoplasms 1Neoplasm Metastasis 1Hemangiosarcoma 1HER2-positive Breast Cancer 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1Biliary Tract Neoplasms 1

Interventions

pembrolizumab 4Nivolumab 3Itraconazole 2tucatinib 1tremelimumab 1regorafenib 1pertuzumab 1lenvatinib 1larotrectinib 1durvalumab 1cemiplimab 1brigimadlin 1aflibercept 1Trastuzumab 1Ritonavir 1Paclitaxel 1Fulvestrant 1Clinical Trials, Phase II as Topic 1Carboplatin 1Capecitabine 1Antibodies 1AZD9833 1AZD5305 1AZD 6244 1ARX788 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Biliary Tract Neoplasms × ARX788 × Breast × Clear all
NCT05041972 2022-09-13

ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)

Ambrx, Inc.

Phase 2 Withdrawn
BreastGastrointestinalThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡